Milwaukee Health Department warns of skin disease from unlicensed tattoo operation
The Milwaukee Health Department is investigating unlicensed tattoo operations after cases of skin disease in minors emerged.
The health department said it started investigating the case after a report on May 14 from a medical provider of a case of nontuberculous mycobacteria from a tattoo procedure on a minor.
The health department said they found two additional cases of minors with NTM on May 20 and June 2.
The health department teamed up with the Milwaukee Police Department to find one of the suspects, according to Carly Hegarty, director of consumer environmental health for the City of Milwaukee.
Citations were issued against Jonathan Beasley accusing him of giving tattoos to minors without a license. He faces $614 in fines. MPD and health officials connected Beasley to two locations associated with Davinci Way Ink.
NTM is an environmental bacterium that can cause a skin infection. NTM can come from tattooing if the tattoo tools aren't properly cleaned or used in unsterile tap water used to distill the black ink, according to a health department press release.
According to Hegarty, the symptoms of NTM are swelling, pain, and pus and drainage near the tattoo area.
While NTM can heal in two to three months, Hegarty said anyone who believes they have NTM should get an official diagnosis and treatment from a doctor.
The Milwaukee Health Department is urging medical professionals to report if they see cases of tattoo-related infections and to ask their patients about recent tattoos and where they obtained them.
Investigations into other unlicensed tattoo operations are still ongoing, Hegarty said.
For parents or other people interested in tattoo safety, Hegarty said there are a few signs people can look for to be safe.
According to the press release, licensed tattoo artists are supposed to verify the age of the person receiving the tattoo, follow proper sanitation procedures and give detailed instructions for aftercare.
Hegarty said when getting tattoos, regardless of age, it's important to advocate for yourself.
'People absolutely have the right to ask, hey, can I see your City of Milwaukee-issued license? Can I see your practitioner's license? I would say good any tattoo artist would have that readily available,' Hegarty said.
This article originally appeared on Milwaukee Journal Sentinel: Cases of skin disease from illegal tattoo operation in Milwaukee
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Nontuberculous Mycobacterial (NTM) Diagnostic Market to Reach USD 3,261.1 million By 2032, Growing At An 6.64% CAGR
PUNE, India, June 9, 2025 /PRNewswire/ -- According to the latest research by Credence Research, the global Nontuberculous Mycobacterial (NTM) Diagnostic Market was valued at USD 1,814.8 million in 2023 and is projected to reach USD 3,261.1 million by 2032, growing at a compound annual growth rate (CAGR) of 6.64% during the forecast period. The rising incidence of NTM infections, especially among immunocompromised patients and individuals with chronic pulmonary conditions, is a primary factor driving market demand. Technological advancements in molecular diagnostics and imaging techniques are significantly enhancing detection accuracy and speed, leading to faster diagnosis and improved clinical outcomes. Healthcare providers are increasingly adopting advanced diagnostic platforms to address the complexities of identifying NTM species, which often mimic other pulmonary disorders. This shift is further supported by growing awareness of NTM-related diseases and stronger clinical guidelines for early screening and diagnosis. Expanding healthcare infrastructure across emerging markets, coupled with increased investments in R&D by diagnostics companies, is expected to accelerate market expansion over the coming years. Browse the report and understand how it can benefit your business strategy- Key Growth Determinants: Nontuberculous Mycobacterial (NTM) Diagnostic Market The growth of the NTM Diagnostic Market is primarily driven by the rising global prevalence of NTM infections, particularly among the aging population and individuals with underlying lung conditions such as COPD, bronchiectasis, and cystic fibrosis. As awareness of these infections increases among healthcare professionals, the demand for timely and accurate diagnostic solutions is expanding. This trend is supported by an uptick in hospital admissions and outpatient consultations related to unexplained pulmonary symptoms, where NTM is an emerging differential diagnosis. Another key growth determinant is the rapid advancement in diagnostic technologies. Innovations in molecular diagnostics, PCR-based assays, and next-generation sequencing (NGS) are enabling faster, more precise identification of various NTM species, overcoming the limitations of traditional culture methods. Furthermore, increased funding for infectious disease research and growing collaborations between public health organizations and diagnostic manufacturers are creating favorable conditions for product development and market penetration. The rising implementation of clinical guidelines recommending early testing for at-risk populations is also bolstering the adoption of advanced NTM diagnostics globally. Key Growth Barriers: Nontuberculous Mycobacterial (NTM) Diagnostic Market Limited Awareness and MisdiagnosisMany clinicians and patients remain unaware of NTM infections, which often mimic tuberculosis or other chronic pulmonary conditions. This lack of awareness leads to frequent misdiagnosis or delayed testing, particularly in settings with limited diagnostic infrastructure. Diagnostic Complexity and InaccessibilityAccurate identification of NTM species is essential for effective treatment, but traditional culture methods are time-consuming and may lack sensitivity. Advanced molecular diagnostic tools, though more effective, are not widely accessible in many regions, especially in developing markets. Resource Constraints in Healthcare FacilitiesComprehensive NTM diagnostics require specialized laboratory equipment, trained personnel, and standardized testing protocols. Many healthcare systems, especially in low- and middle-income countries, face limitations in implementing such advanced diagnostics. Regulatory and Reimbursement ChallengesNavigating regulatory approval for new diagnostic tools can be time-consuming and costly. In addition, limited reimbursement policies for advanced NTM diagnostic tests discourage healthcare providers from adopting innovative solutions. Segmentation Based on Diagnostic Method: Nucleic Acid Amplification Tests (NAAT) Microscopy Culture-based Methods Biochemical Tests Immunological Tests PCR Others Based on Infection Type: Pulmonary Cutaneous Disseminated Gastrointestinal Others Based on End-User: Hospitals & Clinics Diagnostic Laboratories Others Based on region North America Europe Asia Pacific Latin America Middle East & Africa Preview the report with a detailed sample and understand how it can benefit your business strategy. Request a free sample today - Regional Analysis: Nontuberculous Mycobacterial (NTM) Diagnostic Market North America holds the largest share of the global NTM Diagnostic Market, accounting for approximately 39% of total revenue in 2023. This dominance is driven by advanced healthcare infrastructure, widespread use of molecular diagnostic technologies, and high awareness of NTM-related diseases. The presence of major diagnostic companies and strong R&D funding further support market growth in the United States and Canada. Europe follows with around 27% of the market share. Countries like Germany, the UK, and France are key contributors, supported by growing recognition of NTM infections, aging populations, and well-established public health systems. Increased focus on early diagnosis and the adoption of advanced testing tools continue to fuel regional demand. Asia-Pacific accounts for roughly 23% of the global market. Rapid improvements in healthcare infrastructure, growing patient awareness, and increased investments in diagnostic technologies are propelling growth in China, Japan, South Korea, and India. Partnerships between international diagnostic firms and regional players are expanding access to accurate NTM testing. Latin America represents about 6% of the market, led by Brazil, Mexico, and Argentina. Market growth is supported by public health campaigns and improved diagnostic capabilities, though infrastructure disparities in remote areas remain a challenge. Middle East & Africa comprise the smallest share, approximately 5% in 2023. While diagnostic capacity remains limited in many parts of the region, targeted investments in laboratory services and healthcare modernization—especially in the GCC and South Africa—are gradually improving market potential. Credence Research's Competitive Landscape Analysis Credence Research's Competitive Landscape Analysis presents a clear and focused view of key industry players in the NTM diagnostic segment with a spotlight on strategic strengths and market positioning: Credence Research identifies a handful of dominant multinational diagnostics firms—Thermo Fisher Scientific Inc., F. Hoffmann‑La Roche Ltd, Becton, Dickinson & Company (BD), and bioMérieux SA—as frontrunners in the global NTM diagnostic market. These companies differentiate themselves via wide-ranging product portfolios that encompass both molecular and immunological diagnostic tools. They cater to centralized laboratory settings and decentralized testing environments, ensuring flexibility across different healthcare infrastructures. Their strong investment in R&D, global distribution networks, and robust service support contribute to their sustained competitive edge and rapid product adoption. Through its analysis, Credence Research highlights how these industry leaders are not only maintaining market dominance but also expanding access to advanced NTM diagnostic solutions via collaborations, innovative product development, and targeted regional strategies—positioning themselves to capitalise on the projected market growth. Tailor the report to align with your specific business needs and gain targeted insights. Request Full Report Here- Key Player Analysis Thermo Fisher Scientific Inc Hoffmann-La Roche Ltd Becton, Dickinson and Company (BD) bioMérieux SA Bruker Corporation SD Biosensor Bioneer Seegene Inc. Recent Industry Developments June 2025 – Thermo Fisher Scientific introduced two advanced mass spectrometry instruments—the Orbitrap Astral Zoom and Orbitrap Excedion Pro—during the ASMS conference. Designed primarily for proteomics and biopharma applications, these systems deliver enhanced speed and sensitivity, significantly advancing the analysis of complex biological samples. Their improved resolution and throughput have potential applications in infectious disease diagnostics, including NTM-related testing. December 2024 – Shanghai MicuRx Pharmaceutical ( announced that the U.S. FDA granted Orphan Drug Designation (ODD) to its investigational anti-infective drug MRX-5 for the treatment of NTM infections, representing a significant step in developing targeted therapies for this condition. September 2023 – QIAGEN entered a strategic partnership with a major South Asian healthcare provider to integrate its proprietary diagnostics into regional laboratories, enhancing capabilities for detecting and managing NTM infections. August 2023 – bioMérieux expanded its infectious disease portfolio through the acquisition of a biotech company specializing in NTM diagnostics. July 2023 – Hologic, Inc. secured regulatory approval for a new diagnostic test specifically developed to identify NTM infections, reinforcing its commitment to infectious disease diagnostics. January 2022 – Gaelan Medical Trade LLC partnered with RedHill Biopharma Ltd. to distribute Talicia (omeprazole magnesium, amoxicillin, and rifabutin) in the United Arab Emirates. Though primarily approved for H. pylori, its components hold relevance in mycobacterial infection strategies. February 2021 – Koninklijke Philips N.V. completed the acquisition of BioTelemetry, Inc., a leader in remote monitoring and diagnostics, potentially expanding future integration of infectious disease tracking technologies. Reasons to Purchase this Report: Gain a comprehensive understanding of the market through qualitative and quantitative analyses, considering both economic and non-economic factors, with segmentation and sub-segmentation details provided in terms of market value (USD Billion). Identify regions and segments expected to experience the fastest growth or dominate the market, with a detailed analysis of geographic consumption patterns and the factors driving or hindering market performance in each region. Stay informed about the competitive environment, with rankings of major players, recent product and service launches, partnerships, business expansions, and acquisitions from the past five years. Access detailed profiles of major market players, including company overviews, insights, product benchmarking, and SWOT analysis, to understand competitive advantages and market positioning. Explore the present and forecasted market landscape, with insights into growth opportunities, market drivers, challenges, and constraints for both developed and emerging regions. Benefit from Porter's Five Forces analysis and Value Chain insights to evaluate various market perspectives and competitive dynamics. Understand the evolving market scenario, including potential growth opportunities and trends expected in the coming years. Browse the report and understand how it can benefit your business strategy - Discover additional reports tailored to your industry needs Ocular Drug Delivery System Market - Pharma Grade Synthetic Camphor Market - Topical Drug Delivery Market - Lidocaine Market - Dermatology and Eye Care Services Market - Metabolism Assays Market - Dental Implantology Drill Bit Market - Dental Implantology Drill Bit Market - Tetrabenazine Market - Follow Us: About Us: Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. Contact Us Mitul DeanTower C-1105 , S 25, Akash Tower,Vishal Nahar, Pimple Nilakh, Haveli,Pune – 411027, Indiasales@ Logo - View original content to download multimedia: SOURCE Credence Research Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Milwaukee Health Department warns of skin disease from unlicensed tattoo operation
The Milwaukee Health Department is investigating unlicensed tattoo operations after cases of skin disease in minors emerged. The health department said it started investigating the case after a report on May 14 from a medical provider of a case of nontuberculous mycobacteria from a tattoo procedure on a minor. The health department said they found two additional cases of minors with NTM on May 20 and June 2. The health department teamed up with the Milwaukee Police Department to find one of the suspects, according to Carly Hegarty, director of consumer environmental health for the City of Milwaukee. Citations were issued against Jonathan Beasley accusing him of giving tattoos to minors without a license. He faces $614 in fines. MPD and health officials connected Beasley to two locations associated with Davinci Way Ink. NTM is an environmental bacterium that can cause a skin infection. NTM can come from tattooing if the tattoo tools aren't properly cleaned or used in unsterile tap water used to distill the black ink, according to a health department press release. According to Hegarty, the symptoms of NTM are swelling, pain, and pus and drainage near the tattoo area. While NTM can heal in two to three months, Hegarty said anyone who believes they have NTM should get an official diagnosis and treatment from a doctor. The Milwaukee Health Department is urging medical professionals to report if they see cases of tattoo-related infections and to ask their patients about recent tattoos and where they obtained them. Investigations into other unlicensed tattoo operations are still ongoing, Hegarty said. For parents or other people interested in tattoo safety, Hegarty said there are a few signs people can look for to be safe. According to the press release, licensed tattoo artists are supposed to verify the age of the person receiving the tattoo, follow proper sanitation procedures and give detailed instructions for aftercare. Hegarty said when getting tattoos, regardless of age, it's important to advocate for yourself. 'People absolutely have the right to ask, hey, can I see your City of Milwaukee-issued license? Can I see your practitioner's license? I would say good any tattoo artist would have that readily available,' Hegarty said. This article originally appeared on Milwaukee Journal Sentinel: Cases of skin disease from illegal tattoo operation in Milwaukee
Yahoo
03-06-2025
- Yahoo
Search warrant leads to seizure of firearms, 3D printers, drugs in Wisconsin
MILWAUKEE, Wis. (WFRV) – A search warrant led to the discovery of several illegal items at the end of May in southeast Wisconsin. According to the Milwaukee Police Department, officers, in conjunction with other personnel assigned to the North Central High Intensity Drug Trafficking Areas (HIDTA) program, served a search warrant on Milwaukee's north side on May 30. Man arrested after leading Wisconsin deputies on pursuit, getting stuck in field The following items were confiscated as a result of the search: Nine pistol machine gun conversion devices Five rifle auto-sears 16 pistols Three rifles Four rifle suppressors Five pistol suppressors 14 3D printers 16.37 grams of psilocybin mushrooms Man arrested after leading Wisconsin deputies on pursuit, getting stuck in field The HIDTA program, created by Congress with the Anti-Drug Abuse Act of 1988, provides assistance to federal, state, local, and tribal law enforcement agencies operating in areas determined to be critical drug-trafficking regions of the United States. For more information on the program, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
